Mendelspod Podcast

Wait! What? Sequencing as a service?

That was the reaction when Mark Budde first set out to upend a basic ritual in mol…

Just weeks before the FDA’s sweeping rule to regulate laboratory-developed tests (LDTs) was set to take effect, a federal court struck it down. What does this mean for the field of precision medicine…

In today’s show, Theral is joined by Chris Petersen, Chief Technology Officer at Scientist.com, a company sometimes called the "Amazon for science"—though with a great deal more complexity. Chris pul…

In today’s program, we continue our series on disease subtyping with Dr. Jeffery Klco, a pediatric pathologist and researcher at St. Jude Children’s Research Hospital. Dr. Klco joins us to discuss gr…

Dr. Aaron Viny, oncologist and researcher at Columbia University, begins today’s conversation with a personal milestone—he’s now been leukemia-free for 21 years. This experience gives his work on can…

We’re happy to welcome back Ben Busby, Principal Scientist at DNAnexus, to dive deeper into the evolving world of disease subtyping and multi-omic data sets. Building on our previous conversation wit…

John Cumbers, founder of SynBioBeta, joins Theral for our annual look ahead at the field of synthetic biology and the upcoming SynBioBeta 2025 conference, happening May 6–9 in San Jose. It's obviousl…

Today Theral is joined by returning guests Chris Mason of Weill Cornell Medicine and Simon Fredriksson, CEO of Pixelgen Technologies, for a deep dive into the emerging field of cell surface proteomic…

In our last episode, we explored the growing shift from genomics to multi-omics. But for Pacific Biosciences CEO Christian Henry, the foundation of discovery remains clear: “DNA is still where it’s a…

It’s time for our annual deep dive into sequencing—no, wait—multi-omics! Back on the show is our resident sequencing gu…

This week on Mendelspod, as we celebrate International Women’s Day, we’re spotlighting groundbreaking contributions from women in science. Our guest, Dr. Mirna Ghemrawi, is at the forefront of forens…

In this urgent and unflinching conversation, Stanford law professor Hank Greely returns to Mendelspod to address the mounting threats of the Trump administration to public science funding and the ins…

For decades, drug developers have struggled with so-called "undruggable" proteins—those regions of the proteome that evade traditional small molecules and antibodies. But Aikium, led by Eswar Iyer, c…

Today Theral talks with Laura Hercher, Director of Research for Human Genetics at Sarah Lawrence College, about the growing political assault on diversity, equity, and inclusion (DEI) initiatives in …

Lung cancer is the most deadly of all the cancers worldwide. Very few of those who should be— are getting screened. The…

In our first conversation with Deep Genomics, Theral sits down with Brendan Frey, the company's founder and Chief Innov…

In this Mendelspod episode, Theral explores the state of genome informatics with Ben Busby, principal scientist at DNAnexus.

Busby reflects on his journey into the field, which was influenced by key p…

As 2025 begins, we are launching a new series The New Genetic Testing. To do that we’re welcoming today Dr. Ezra Cohen,…

This week we welcome the innovative minds behind PredixBio, a new and groundbreaking company at the forefront of spatia…

This year in a series co-produced with GenomeWeb we had an exclusive look into Illumina’s work in genomic AI with Kyle Farh, the VP and Distinguished Scientist leading the Illumina Artificial Intelli…